Merck(US:MRK) 智通财经网·2026-01-09 05:37Group 1 - Wolfe Research upgraded Merck & Co. (MRK.US) from "in line with peers" to "outperform," setting a target price of $135 [1] - Analyst Alexandria Hammond noted that Merck is well-positioned to handle the impending loss of exclusivity for its blockbuster cancer drug Keytruda's intravenous version [1] - Based on physician feedback, it is expected that by 2029, Merck will convert 41% of Keytruda's intravenous revenue to its newly approved subcutaneous version, Qlex, leading to a $6 billion increase in Keytruda's revenue forecast for 2030 compared to market consensus [1] Group 2 - Merck is reportedly in talks to acquire biotechnology company Revolution Medicines (RVMD.US), with a potential deal price between $28 billion and $32 billion [2] - If the acquisition is completed, it would be one of the largest pharmaceutical deals since Pfizer's $43 billion acquisition of Seagen at the end of 2023 [2] - Since 2021, Merck's late-stage product line has nearly doubled due to internal development and large transactions, such as the $11.5 billion acquisition of Acceleron [2] Group 3 - Wolfe Research downgraded AbbVie (ABBV.US) from "outperform" to "in line with peers," removing the previous target price of $275 [2] - The downgrade reflects the belief that AbbVie's stock price has fully accounted for the strong performance of its new immunology products, Skyrizi and Rinvoq [2] - Skyrizi and Rinvoq have become the dominant forces in AbbVie's immunology and inflammation portfolio following the patent cliff of the blockbuster drug Humira [2]